Table 1.

Major RCTs in the field.

Study Title	Participants	Intervention	Duration	Comparison	Main Findings
1. HPS (Heart Protection Study) [70]	20,536 patients (High-risk individuals)	Simvastatin 40 mg/d	5.3 years	Placebo	This randomized controlled trial assessed the impact on 11-year mortality and morbidity. Statin use reduces major vascular events.
2. ASCOT-LLA (Anglo-Scandinavian Cardiac Outcomes TrialLipid-Lowering Arm) [71]	10,305 patients (Hypertensive patients)	Atorvastatin 10 mg/d	Mean 3.3 years	Placebo	Atorvastatin reduces cardiovascular events in hypertensive patients.
3. JUPITER (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin) [20]	17,802 participants (High-risk individuals)	Rosuvastatin 20 mg/d	Average 2 years	Placebo	Rosuvastatin reduces cardiovascular events in individuals with elevated hs-CRP without a systematic rise in reported adverse events.
4. PROVE-IT TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22) [72]	4162 patients (post-ACS patients)	Pravastatin 40 mg/d vs. Atorvastatin 80 mg/d	Median 2 years	Intensive vs. moderate statin therapy	Intensive statin therapy (Atorvastatin) reduces cardiovascular events more than moderate therapy (Pravastatin).
5. TNT (Treating to New Targets) [73]	10,001 patients (stable coronary heart disease)	Atorvastatin 10 mg/d vs. 80 mg/d	Median 4.9 years	Standard vs. high-dose statin therapy	High-dose Atorvastatin is more effective in reducing cardiovascular events.